Celxcel, a regenerative tissue engineering technology company founded in 2001 that has completed a Phase II human clinical trial for its lead product CardioCel.
CardioCel is a cardiovascular patch used to repair paediatric heart deformities. These deformities range from simple “Hole in the Heart” operations to major vessel outflow tract repairs. The CardioCel patch may also be used to repair leaking heart valves in paediatric patients.
Celxcel uses its patented ADAPT Tissue Engineering Process (TEP) as a platform technology to produce implantable tissue patches for use in various soft tissue repair applications and for the production of replacement tissue heart valves .
The ADAPT technology is used to process animal derived tissues to produce implantable tissue patches that are compatible with the human body. This technology has the potential for medical professionals to use regenerative products instead of synthetic products currently used in soft tissue repair.
Celxcel is evaluating the ADAPT process for use in other surgical applications such as hernia repair, pelvic floor repair, and orthopaedic soft tissue repair.